Previous 10 | Next 10 |
SCYNEXIS (NASDAQ: SCYX ): Q1 GAAP EPS of -$0.07 beats by $0.08 . More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is on track for the second half ...
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate oral ibrexafungerp could potentially decrease length of hospital stays by reducing de...
SCYNEXIS (NASDAQ: SCYX ) has filed a prospectus for a 19.4M common shares from stockholders. More news on: SCYNEXIS, Inc., Healthcare stocks news, , Read more ...
JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executiv...
SCYNEXIS (NASDAQ: SCYX ) announces positive results from a second Phase 3 clinical trial, VANISH-306 , evaluating oral ibrexafungerp, a broad-spectrum antifungal, in women with vulvovaginal candidiasis (vaginal yeast infection). More news on: SCYNEXIS, Inc., Healthcare stocks news, Stoc...
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints Ibrexafungerp was generally safe and well-tolerated Positive results consistent with previously reported VANISH-303 study support anticipated NDA submi...
SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital $20 million purchase agreement, combined with $10 million cash injection from recent sale of convertible notes, affords additional financial flexibility and significantly strengthens SCYNEX...
JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 (the ...
JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Nkechi Azie, SCYNEXIS’s VP of Clinical Devel...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...